Roche Among EU Fast-Track Hopefuls With Lymphoma Bispecific Mosunetuzumab
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
You may also be interested in...
The European Medicines Agency was this week deciding whether to grant accelerated assessment for glofitamab.
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
The Pink Sheet's EU accelerated assessment tracker has been updated to include developments relating to investigational products from, among others, Janssen, Sanofi, Boehringer Ingelheim and Mirum.